Benzinga | Aug 9, 2021 08:21AM EDT

aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company's lead therapeutic candidate, ATYR1923, have been accepted for presentation at the 2021 European Respiratory Society International Congress to be held virtually September 5 -- 8.



Details of the presentations are as follows:

Title: Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia

Authors: Ryan Adams, Gennyne Walker, Lauren Guy, Lauren Sitts, Nelson Kinnersley, Lisa Carey, Leslie Nangle, Sanjay Shukla. aTyr Pharma, San Diego, CA, Octa Consulting Services, Harpenden, United Kingdom.

Session Title: Diagnosis and Management of COVID-19

Presentation Format: E-poster

Presentation Date and Time: September 5, 2021 from 7:15AM -- 8:15AM ET

Title: Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation

Authors: Suzanne Paz, Mark W. Julian, David Siefker, Erik Escobedo, Michaela Ferrer, Clara Polizzi, Lauren Guy, Christoph Burkart, Ryan Adams, Leslie Nangle, Elliott D. Crouser. aTyr Pharma, San Diego, CA, Ohio State University Wexner Medical Center, Columbus, Ohio.

Session Title: Better Understanding of Sarcoidosis: New Keys

Presentation Format: Oral Presentation

Presentation Date and Time: September 7, 2021 from 9:35AM -- 9:40AM ET

Full text of the abstracts will be available on the conference website on August 23, 2021.